Good morning. My name is Christy and I will be your conference operator today. At this time, I would like to welcome everyone to the EDAP second quarter 2008 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator instructions) I will now turn the call over to Mr. R.J. Pellegrino of Ruth Group; sir, please go ahead.

Thank you, operator. With us today from management are Philippe Chauveau, Chairman of the Board; Marc Oczachowski, Chief Executive Officer; and Eric Soyer, Chief Financial Officer. By now you should have received a copy of the earnings press release. If you have not received a copy, please call Zack Kubow at 646-536-7020 and he will fax or email you a copy. Before we begin, I would like to remind everyone that management’s remarks today may contain certain forward-looking statements. Complete details of factors affecting forward-looking statements can be found in the company’s SEC filings available at the company’s website at www.edap-tms.com and are incorporated by reference for all remarks made during the course of this call. With that, I will now turn the call over to Philippe Chauveau, EDAPs Chairman of the Board.

Good morning all. As usual I would like to share some opening remarks; first HIFU. HIFU; despite a flat first half of the year, EDAPs HIFU at the standard of care is outstanding and Q3 and Q4 will continue to show this with our RPP aggressive growth program which is up and running in the four major European countries. Further in the U.S. the future of Ablatherm Robotech HIFU as evidence in the progress of our patient enrollment is unquestionably strong. Additionally our new HIFU product pipeline is also excitingly promising. Second little Lithotripsy; the success of our next-generation Sonolith-I-sys is not proven with robust revenue growth in Q2. Third Chinamed; I am also please that our partnership with Chinamed in Europe is firmly on track and doing well. Finally I would to like reemphasize that our first half of 2008, there is no reflection on EDAPs strength and right future, over to Marc.

Thank you, Philippe, and thank you everyone for joining us on our second quarter 2008 earnings call. We are encouraged by our Lithotripsy sales growth during the second quarter that has risen by the continued penetration of our next-generation Sonolith I-Sys device. As outlined in our release quarterly totally lithotripsy revenue increased 47.9% sequentially reflecting the anticipated higher than growth machine sales consistent with our first quarter guidance. After reviewing our strong performance in lithotripsy, I will outline some of our sales and marketing initiatives that we believe will stimulate growth of HIFU sales and then I will discuss our progress on patient enrolment in the U.S. ENLIGHT trial as we advance towards pre market approval submission to the FDA for our Ablatherm Robotic HIFU device. Let me start with lithotripsy. During the second quarter we experienced strong revenue growth in our lithotripsy division highlighted a 47.9% sequential increase in sales. As mentioned in our earnings release we sold ten machines including two Sonolith I-Sys devices. As anticipated we converted much of our first quarter 2008 backlog into revenue during the second quarter. The enthusiasm for Sonolith I-Sys from our customers is enormous as the device provides superior imaging and software systems, as well as user friendly features associated with high efficacy treatment offering the best standards for the benefits of both the patient and the hospital. Outside of the U.S. we remain focused on increasing the awareness and adoption of our products through aggressive sales and marketing initiatives. During the quarter we capitalized on the opportunities to further demonstrate the advantages of HIFU as a prudent therapeutic option by attending several events with the world’s most renowned national and international opinion leaders in Urology. EDAP has a very strong presence at both the American Urological Association and the British…

Total revenue for the second quarter of 2008, was EUR 5 million compared to EUR 5.9 million for the same period of 2007. This figure was primarily impacted by a challenging year-over-year revenue comparison due to no sales of Ablatherm-HIFU system versus two in the second quarter of 2007 including high-priced units. Total revenue for the HIFU division was EUR 1.6 million in the second quarter of 2008, compared to EUR 2.8 million in the same period of last year. On the six months comparable basis, HIFU capital equipment sales remained flat in terms of units sold with two machines sold. As Marc noted in his comments, we have implemented an aggressive RPP program in response to the stabilization of HIFU RPP sales in the first and second quarter of 2008 but we are confident our action plan will drive RPP sales in the second half of 2008. Net sale for the Lithotripsy division, was EUR 3.3 million in the second quarter of 2008 compared to a EUR 3.1 million in the year ago period. Consistent with our first quarter 2008 statement indicating that seven machines were in backlog, including two Sonolith I-sys devices, the increase reflected higher machine sales as we converted much of the backlog into revenue and sold ten lithotripsy devices during the second quarter of 2008. As Marc noted, our current backlog of eight machines including five Sonolith I-sys devices strongly position us to continue driving lithotripsy sales in the third and fourth quarter of 2008. Similar to the patents we experienced during the quarter we expect to convert the majority of our backlog into revenue during the third and fourth quarter of this year. Our gross profit for the second quarter was EUR 1.9 million compared EUR 2.3 million in the year ago periods. Gross…

(Operator instructions) There are no questions at this time. I will now turn the conference back over to Mr. Marc Oczachowski for any closing remarks.

In conclusion, we are pleased with the strong sales performance of our lithotripsy division in the quarter and believe our reverse backlog as of June 30, 2008 leave us well position to drive increased sales growth in the second half of the year. We have identified a plan of action to increase our RPP sales efforts and are already encouraged by the sale of one Ablatherm-HIFU device in August. We continue to make progress on our U.S. ENLIGHT clinical trial and expect treatment volumes to ramp up as we moving to the third quarter. Thank you again all for attending the call.

This does conclude today’s conference call. You may now disconnect.